Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 2/20 | 0.65 |
| ▸ | DOT1L | Q8TEK3 | 2/20 | 0.65 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.61 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.49 |
| ▸ | PAK4 | O96013 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | LCK | P06239 | 1/20 | 0.49 |
| ▸ | FYN | P06241 | 1/20 | 0.49 |
| ▸ | CSF1R | P07333 | 1/20 | 0.49 |
| ▸ | RET | P07949 | 1/20 | 0.49 |
| ▸ | IGF1R | P08069 | 1/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.49 |
| ▸ | PRKACA | P17612 | 1/20 | 0.49 |
| ▸ | FLT1 | P17948 | 1/20 | 0.49 |
| ▸ | LTK | P29376 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.49 |
| ▸ | FLT3 | P36888 | 1/20 | 0.49 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14598185 | 1.00 | ADK (0.65) | ADKDOT1LADORA2ADAPK3MAP4K4 | |
| SCHEMBL14598205 | 1.00 | ADK (0.65) | ADKDOT1LADORA2ADAPK3MAP4K4 | |
| SCHEMBL14523017 | 1.00 | ADK (0.65) | ADKDOT1LADORA2ADAPK3MAP4K4 | |
| SCHEMBL14598223 | 1.00 | ADK (0.65) | ADKDOT1LADORA2ADAPK3MAP4K4 | |
| SCHEMBL4429311 | 1.00 | ADK (0.65) | ADKDOT1LADORA2ADAPK3MAP4K4 | |
| SCHEMBL14598204 | 1.00 | ADK (0.65) | ADKDOT1LADORA2ADAPK3MAP4K4 | |
| SCHEMBL14523024 | 0.92 | ADK (0.57) | ADKDOT1LADORA2ADAPK3MAP4K4 | |
| SCHEMBL14523037 | 0.90 | ADORA2A (0.59) | ADKDOT1LADORA2AADORA3ADORA1 | |
| SCHEMBL5520162 | 0.90 | ADORA2A (0.59) | ADKDOT1LADORA2AADORA3ADORA1 | |
| SCHEMBL12447395 | 0.90 | ADORA2A (0.61) | ADKDOT1LADORA2ACDK5PRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7169918-B2 | Methods for preparing 7-(2′-substituted-β-D-ribofuranosyl)-4-(NR2R3)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivatives | GENELABS TECHNOLOGIES, INC. (US) | 2007-01-30 | — | — | US | claimed |
| US-7157434-B2 | Nucleoside compounds for treating viral infections | GENELABS TECHNOLOGIES, INC. (US) | 2007-01-02 | — | — | US | claimed |
| EP-1682564-A1 | METHODS FOR PREPARING 7-(2 -SUBSTITUTED-s-D-RIBOFURANO SYL)-4-(NR2R3)-5-(SUBSTITUTED ETHYN-1-YL)-PYRROLO 2,3-D|PYRIMIDINE DERIVATIVES | GENELABS TECHNOLOGIES, INC. (US) | 2006-07-26 | — | — | EP | claimed |
| US-20060079468-A1 | Nucleoside compounds for treating viral infections | GENELABS TECHNOLOGIES, INC. | 2006-04-13 | — | — | US | claimed |
| US-20050215510-A1 | Methods for preparing 7-(2'-substituted-beta-D-ribofuranosyl)-4-(NR2R3)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivatives | GENELABS TECHNOLOGIES, INC. | 2005-09-29 | — | — | US | claimed |
| WO-2005044835-A1 | METHODS FOR PREPARING 7-(2'-SUBSTITUTED-ß-D-RIBOFURANOSYL)-4-(NR2R3)-5-(SUBSTITUTED ETHYN-1-YL)-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | GENELABS TECHNOLOGIES, INC. (US) | 2005-05-19 | — | — | WO | claimed |
| US-20050107312-A1 | Nucleoside compounds for treating viral infections | GENELABS TECHNOLOGIES, INC. | 2005-05-19 | — | — | US | claimed |
| US-20110306573-A1 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF VIRAL POLYMERASES | MERCK SHARP & DOHME CORP. | 2011-12-15 | — | — | US | disclosed |
| WO-2010015637-A1 | NEW ANTIVIRAL MODIFIED NUCLEOSIDES | NOVARTIS AG (CH) | 2010-02-11 | — | — | WO | disclosed |
| WO-2010015637-A1 | NEW ANTIVIRAL MODIFIED NUCLEOSIDES | NOVARTIS AG (CH) | 2010-02-11 | — | — | WO | disclosed |
| WO-2007084157-A2 | NUCLEOSIDE PRODRUGS FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2007-07-26 | — | — | WO | disclosed |
| US-20070167383-A1 | NUCLEOSIDE COMPOUNDS FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. | 2007-07-19 | — | — | US | disclosed |
| US-7244713-B2 | Nucleoside compounds for treating viral infections | GENELABS TECHNOLOGIES, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| US-7169918-B2 | Methods for preparing 7-(2′-substituted-β-D-ribofuranosyl)-4-(NR2R3)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivatives | GENELABS TECHNOLOGIES, INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-7169918-B2 | Methods for preparing 7-(2′-substituted-β-D-ribofuranosyl)-4-(NR2R3)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivatives | GENELABS TECHNOLOGIES, INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-7157434-B2 | Nucleoside compounds for treating viral infections | GENELABS TECHNOLOGIES, INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-20060079468-A1 | Nucleoside compounds for treating viral infections | GENELABS TECHNOLOGIES, INC. | 2006-04-13 | — | — | US | disclosed |
| US-20050215510-A1 | Methods for preparing 7-(2'-substituted-beta-D-ribofuranosyl)-4-(NR2R3)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivatives | GENELABS TECHNOLOGIES, INC. | 2005-09-29 | — | — | US | disclosed |
| US-20050215511-A1 | Nucleoside compounds for treating viral infections | GENELABS TECHNOLOGIES, INC. | 2005-09-29 | — | — | US | disclosed |
| US-20050107312-A1 | Nucleoside compounds for treating viral infections | GENELABS TECHNOLOGIES, INC. | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167383-A1 | NUCLEOSIDE COMPOUNDS FOR TREATING VIRAL INFECTIONS | PNP, HAVCR2, SAMHD1 | ADK 190/4885DOT1L 2129/4885ADORA2A 235/4885 |
| US-20050107312-A1 | Nucleoside compounds for treating viral infections | PNP, HAVCR2, SAMHD1 | ADK 190/4885DOT1L 2129/4885ADORA2A 235/4885 |
| US-20060079468-A1 | Nucleoside compounds for treating viral infections | PNP, HAVCR2, SAMHD1 | ADK 190/4885DOT1L 2129/4885ADORA2A 235/4885 |
| US-20050215510-A1 | Methods for preparing 7-(2'-substituted-beta-D-ribofuranosyl)-4-(NR2R3)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivatives | HAVCR2, NR4A3, NR2C2 | ADK 2532/4885DOT1L 3820/4885ADORA2A 738/4885 |
| US-20050215511-A1 | Nucleoside compounds for treating viral infections | PNP, HAVCR2, SAMHD1 | ADK 190/4885DOT1L 2129/4885ADORA2A 235/4885 |
| US-20110306573-A1 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF VIRAL POLYMERASES | POLR2E, POLR2H, POLRMT | ADK 762/4885DOT1L 2374/4885ADORA2A 1395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.